Last updated 2026-07-20
Portfolio
0
in our dataset
Rounds participated
0
Rounds led
0
Rounds' value
—
total disclosed, rounds participated
Stages
—
About
Prof. Nava Zisapel is a renowned neuroscientist, a full professor at Tel-Aviv University specializing in Neuro-biochemistry, and holds the Michael Gluck Chair in Neuropharmacology and ALS Research. She is the founder and Chief Scientific Officer of Neurim Pharmaceuticals, Ltd., a drug discovery and development company focused on central nervous system disorders. She also co-founded RAD BioMed, an Israeli biomedical accelerator.
Portfolio
No portfolio companies in this dataset yet.
Investment activity
1 portfolio exit on record.
Portfolio by sector
Health Tech & Life Sciences4
Q&A
- What is Nava Zisapel's primary investment focus by sector?
- Nava Zisapel primarily focuses on the Health Tech & Life Sciences sector, with all four of her portfolio companies and her single recorded exit falling within this area.
- Can you name some of Nava Zisapel's notable portfolio companies?
- Nava Zisapel's portfolio includes FEMSelect, which develops treatments for Pelvic Floor Ligament Fixation.
- Has Nava Zisapel had any notable exits?
- Yes, Nava Zisapel had a notable exit with Vectorious Medical Technologies, which was acquired by Edwards Lifesciences for $497M in September 2025.
- What stages of funding does Nava Zisapel typically invest in?
- Nava Zisapel has invested across various stages, including Seed rounds, B Rounds, and Convertible Debt rounds.
- When did Nava Zisapel make her most recent investments?
- Nava Zisapel's most recent recorded investment activity was in December 2019.
- What kind of business models do Nava Zisapel's portfolio companies typically have?
- Nava Zisapel's portfolio companies primarily operate with a B2B business model, such as SynVaccine, which designs and constructs viral-based products.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 1991-12 |
|---|
Radar intelligence
Patents
| EPO | 20 |
|---|